Home > Insider Trading > Filing (0000914062-14-000027)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1133416	Galectin Therapeutics Inc	GALT	Pharmaceutical Preparations (2834)	043562325

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1260641	C James Czirr	C/O Galectin Therapuetics, Inc. 4960 Peachtree Industrial Blvd. Ste. 240 Norcross GA 30071	Executive Chairman	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-01-10	42,000	$16.00	9,415,422	No	4	S	Indirect	By 10X Fund, L.P.
Common Stock	Disposition	2014-01-13	58,000	$14.00	9,357,422	No	4	S	Indirect	By 10X Fund, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By 10X Fund, L.P.
No	4	S	Indirect	By 10X Fund, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	844,450	Direct
Common Stock	179,232	Indirect	By Trust

Footnotes

The Issuer is aware of potential short-swing liability issues related to the transaction reported herein and a transaction reported by the Issuer's Executive Chairman that occurred on November 15, 2013. The issuer is taking steps to collect any short-swing profit created by such transactions.
Reflects weighted average price. Range of prices were between $15.68 and $16.35. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein.
Reflects weighted average price. Range of prices were between $13.65 and $14.23. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.